HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) has released highlights from podium presentations made at the 43rd Annual American Society of Clinical Oncology (ASCO) meeting June 1-5 in Chicago. These presentations describe the results of multi-center, international clinical trials of patients with advanced prostate and colorectal cancers, and the use of Circulating Tumor Cell (CTC) measurement to predict patient survival and as an aid to select patients for and monitor the effectiveness of the targeted therapy. The presentations can be viewed from www.asco.org
